Contact Us
Position:Home > News > Industry News >

Nanomedicine could be used to precision medicine for tumors

2017-07-20 16:08 View:
Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.
The strategy involves using lipid polymer based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor initiating cells (BTICs).
"BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy," explained the study's first author, Dr. Dou Yu, research assistant professor of neurological surgery at Northwestern University Feinberg School of Medicine.
The findings were published in the journal Proceedings of the National Academy of Sciences.
Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA)—short sequences of RNA molecules that reduce the expression of specific cancer promoting proteins—directly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.
"This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind," said Yu, who collaborated on the research with principal investigator Dr. Maciej Lesniak, Michael J. Marchese Professor of Neurosurgery and chair of neurological surgery.
Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patient's tumor.
In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissues—but not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.
"This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling," Yu said. "Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits."
The strategy could also apply to other medical conditions related to the central nervous system—not just brain tumors.
"Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform," Yu said.
Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.
"Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer," Lesniak summed up.
Bio-magnetic beads, Sulfydryl modified
Huitong TM Samples mixed instrument|100%
Magnetic beads method glue recovery kit
Nano cerium oxide powder (CeO2 powder)
Nano Tungsten disulfide powder
Tungsten carbide nano powder (99.9% )
Nano Dy2O3 powder
Nano Cobalt powder (Nano Co powder)
Nano Aluminum oxide powder (Nano Al2O3Powder)
Nano Boron carbide powder (Nano CB4 Powder)
Tantalum carbide powder (nano particle size)
Nano titanium(Ti) Powder
Nano Titanium carbide powder (Nano TiC powder)
High purity Nano Manganese(Mn) powder
Nano SiO2 Powder
Nano Fe2O3 powder (99.9%)
Nano Aluminium Nitride powder (Nano AlN powder)
Nano Tungsten disulfide powder (Nano WS2 powder)
chitosan beads
aldehyde beads | aldehyde modified microsphere
Bio-magnetic beads, Carboxylic modified
Bio-magnetic beads, Amino modified
Bio-magnetic beads, Silicic modified
Magnetic fluid
Nano SiO2 dispersing agent
Nano Co dispersing agent
Nano oxidation zinc dispersing agent
Nano silver Soil antibacterial agent
Polyurethane release agents
Nano silver Powder (Nano Ag powder purity 99.99)
Thiadiazole-octyl mercaptan condensates(CAS No: 13539-13-4)
Dimercapto-thiadiazole dimerBis-DMTD
DMTD(2,5- dimercapto-1,3,4- thiadiazole)
Methylene bis (dibutyl dithio carbamate)
MoDTC Complexes (Solid MoDTC)
MoDTP (Liquid Molybdenum Dithiophosphate)
Nano Co dispersing agent
Water-based magnesium stearate
Polyurethane Internal Release Agent
Water-based zinc stearate (Vinyl lubricant )
Stearic acid amides emulsion for themal paper
Water-Based Calcium stearate
Coated with abrasive coating slurry